-----------------------------------------------------------

New Message on Pituitary Chat

-----------------------------------------------------------
From: panatching
Message 3 in Discussion

 Parlodel Side Effects & Drug Interactions      SIDE EFFECTS    
Hyperprolactinemic Indications  
The incidence of adverse effects is quite high (69%) but these are generally 
mild to moderate in degree. Therapy was discontinued in approximately 5% of 
patients because of adverse effects. These in decreasing order of frequency 
are: nausea (49%), headache (19%), dizziness (17%), fatigue (7%), 
lightheadedness (5%), vomiting (5%), abdominal cramps (4%), nasal congestion 
(3%), constipation (3%), diarrhea (3%) and drowsiness (3%).  
A slight hypotensive effect may accompany Parlodel® (bromocriptine mesylate) 
treatment. The occurrence of adverse reactions may be lessened by temporarily 
reducing dosage to ½ SnapTabs® tablet 2 or 3 times daily. A few cases of 
cerebrospinal fluid rhinorrhea have been reported in patients receiving 
Parlodel for treatment of large prolactinomas. This has occurred rarely, 
usually only in patients who have received previous transsphenoidal surgery, 
pituitary radiation, or both, and who were receiving Parlodel for tumor 
recurrence. It may also occur in previously untreated patients whose tumor 
extends into the sphenoid sinus.  
Acromegaly  
The most frequent adverse reactions encountered in acromegalic patients treated 
with Parlodel were: nausea (18%), constipation (14%), postural/orthostatic 
hypotension (6%), anorexia (4%), dry mouth/nasal stuffiness (4%), 
indigestion/dyspepsia (4%), digital vasospasm (3%), drowsiness/tiredness (3%) 
and vomiting (2%).  
Less frequent adverse reactions (less than 2%) were: gastrointestinal bleeding, 
dizziness, exacerbation of Raynaud's Syndrome, headache and syncope. Rarely 
(less than 1%) hair loss, alcohol potentiation, faintness, lightheadedness, 
arrhythmia, ventricular tachycardia, decreased sleep requirement, visual 
hallucinations, lassitude, shortness of breath, bradycardia, vertigo, 
paresthesia, sluggishness, vasovagal attack, delusional psychosis, paranoia, 
insomnia, heavy headedness, reduced tolerance to cold, tingling of ears, facial 
pallor and muscle cramps have been reported.  
Parkinson's Disease  
In clinical trials in which Parlodel was administered with concomitant 
reduction in the dose of levodopa/carbidopa, the most common newly appearing 
adverse reactions were: nausea, abnormal involuntary movements, hallucinations, 
confusion, "on-off'' phenomenon, dizziness, drowsiness, faintness/fainting, 
vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, 
depression, hypotension, shortness of breath, constipation, and vertigo.  
Less common adverse reactions which may be encountered include: anorexia, 
anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, 
erythromelalgia, epileptiform seizure, fatigue, headache, lethargy, mottling of 
skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, 
urinary frequency, urinary incontinence, urinary retention, and rarely, signs 
and symptoms of ergotism such as tingling of fingers, cold feet, numbness, 
muscle cramps of feet and legs or exacerbation of Raynaud's Syndrome.  
Pleural and pericardial effusions, pleural, and pulmonary fibrosis or 
retroperitoneal fibrosis and constrictive pericarditis have been reported 
rarely in patients treated with Parlodel.  
Very rarely, a syndrome resembling Neuroleptic Malignant Syndrome has been 
reported on abrupt withdrawal of Parlodel.  
Abnormalities in laboratory tests may include elevations in blood urea 
nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are 
usually transient and not of clinical significance.  
Adverse Events Observed in Other Conditions  
Postpartum Patients  
In postpartum studies with Parlodel 23 percent of postpartum patients treated 
had at least 1 side effect, but they were generally mild to moderate in degree. 
Therapy was discontinued in approximately 3% of patients. The most frequently 
occurring adverse reactions were: headache (10%), dizziness (8%), nausea (7%), 
vomiting (3%), fatigue (1.0%), syncope (0.7%), diarrhea (0.4%) and cramps 
(0.4%). Decreases in blood pressure (=20 mm Hg systolic and =10 mm Hg 
diastolic) occurred in 28% of patients at least once during the first 3 
postpartum days; these were usually of a transient nature. Reports of fainting 
in the puerperium may possibly be related to this effect. In postmarketing 
experience in the U.S. serious adverse reactions reported include 72 cases of 
seizures (including 4 cases of status epilepticus), 30 cases of stroke, and 9 
cases of myocardial infarction among postpartum patients. Seizure cases were 
not necessarily accompanied by the development of hypertension. An unremitting 
and often progressively severe headache, sometimes accompanied by visual 
disturbance, often preceded by hours to days many cases of seizure and/or 
stroke. Most patients had shown no evidence of any of the hypertensive 
disorders of pregnancy including eclampsia, preeclampsia or pregnancy induced 
hypertension. One stroke case was associated with sagittal sinus thrombosis, 
and another was associated with cerebral and cerebellar vasculitis. One case of 
myocardial infarction was associated with unexplained disseminated 
intravascular coagulation and a second occurred in conjunction with use of 
another ergot alkaloid. The relationship of these adverse reactions to Parlodel 
administration has not been established.  DRUG INTERACTIONS   
The risk of using Parlodel in combination with other drugs has not been 
systematically evaluated, but alcohol may potentiate the side effects of 
Parlodel. Parlodel may interact with dopamine antagonists, butyrophenones, and 
certain other agents. Compounds in these categories result in a decreased 
efficacy of Parlodel: phenothiazines, haloperidol, metoclopramide, pimozide. 
Concomitant use of Parlodel with other ergot alkaloids is not recommended. 

-----------------------------------------------------------

To stop getting this e-mail, or change how often it arrives, go to your E-mail 
Settings.
http://groups.msn.com/PituitaryChat/_emailsettings.msnw

Need help? If you've forgotten your password, please go to Passport Member 
Services.
http://groups.msn.com/_passportredir.msnw?ppmprop=help

For other questions or feedback, go to our Contact Us page.
http://groups.msn.com/contact

If you do not want to receive future e-mail from this MSN group, or if you 
received this message by mistake, please click the "Remove" link below. On the 
pre-addressed e-mail message that opens, simply click "Send". Your e-mail 
address will be deleted from this group's mailing list.
mailto:[EMAIL PROTECTED]

Reply via email to